Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014542 | 1.00 | CYP3A4 (0.46) | CYP3A4DRD2DRD4ATMCNR1 | |
| Trifluoroacetic Acid SCHEMBL1013828 | 0.92 | F2 (0.42) | CYP3A4DRD2DRD4ATMCNR1 | |
| Trifluoroacetic Acid SCHEMBL4662866 | 0.92 | F2 (0.42) | CYP3A4DRD2DRD4ATMCNR1 | |
| SCHEMBL6793000 | 0.88 | FKBP1A (0.46) | CYP19A1 | |
| SCHEMBL22800977 | 0.86 | CYP3A4 (0.50) | CYP3A4MMP2KDM4EL3MBTL1 | |
| SCHEMBL2769632 | 0.82 | CYP3A4 (0.54) | CYP3A4DRD2DRD4ATMCNR1 | |
| Trifluoroacetic Acid SCHEMBL30867894 | 0.82 | FKBP1A (0.42) | CNR2CYP19A1 | |
| SCHEMBL15094620 | 0.81 | MGLL (0.51) | CNR1CNR2KDM4E | |
| SCHEMBL14278251 | 0.80 | MMP2 (0.46) | CNR2MMP2TSHR | |
| SCHEMBL8222304 | 0.80 | MMP2 (0.46) | CNR2MMP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CYP3A4 117/4885DRD2 3034/4885DRD4 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.